MA43767B1 - Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer - Google Patents

Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer

Info

Publication number
MA43767B1
MA43767B1 MA43767A MA43767A MA43767B1 MA 43767 B1 MA43767 B1 MA 43767B1 MA 43767 A MA43767 A MA 43767A MA 43767 A MA43767 A MA 43767A MA 43767 B1 MA43767 B1 MA 43767B1
Authority
MA
Morocco
Prior art keywords
receptor
extracellular domain
alpha chain
directed against
antibodies directed
Prior art date
Application number
MA43767A
Other languages
English (en)
Other versions
MA43767A (fr
Inventor
Nicolas Poirier
Caroline Mary
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of MA43767A publication Critical patent/MA43767A/fr
Publication of MA43767B1 publication Critical patent/MA43767B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps humanisés dirigés contre le domaine extracellulaire de la chaîne alpha du récepteur de l'interleukine-7 (il-7), notamment contre le récepteur de l'il-7 humaine exprimé sur les cellules humaines (également appelé il-7ralpha ou il-7ra ou cd127 humain) et qui n'interfèrent pas avec les voies de signalisation de l'il-7 ou du tslp. Les anticorps de la présente invention ne présentent pas un effet antagoniste sur le récepteur de l'il-7, mais peuvent toujours présenter une activité cytotoxique contre des cellules cd127 positives. Dans un mode de réalisation particulier, l'anticorps ne présente pas un effet agoniste sur le récepteur de l'il-7.
MA43767A 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer MA43767B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (fr) 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et son utilisation dans le traitement du cancer

Publications (2)

Publication Number Publication Date
MA43767A MA43767A (fr) 2019-01-09
MA43767B1 true MA43767B1 (fr) 2019-08-30

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43767A MA43767B1 (fr) 2016-02-29 2017-02-28 Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer

Country Status (22)

Country Link
US (1) US11230602B2 (fr)
EP (1) EP3423496B1 (fr)
JP (1) JP7053479B2 (fr)
KR (1) KR102819051B1 (fr)
CN (1) CN109195987B (fr)
AU (1) AU2017225495B2 (fr)
CY (1) CY1122072T1 (fr)
DK (1) DK3423496T3 (fr)
ES (1) ES2737307T3 (fr)
HR (1) HRP20191445T1 (fr)
HU (1) HUE045183T2 (fr)
IL (1) IL261330B2 (fr)
LT (1) LT3423496T (fr)
MA (1) MA43767B1 (fr)
MD (1) MD3423496T2 (fr)
ME (1) ME03446B (fr)
PL (1) PL3423496T3 (fr)
PT (1) PT3423496T (fr)
RS (1) RS59223B1 (fr)
SI (1) SI3423496T1 (fr)
SM (1) SMT201900460T1 (fr)
WO (1) WO2017149394A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (fr) 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
WO2019043065A1 (fr) * 2017-08-29 2019-03-07 Ose Immunotherapeutics Procédé et préparation permettant de trier des lymphocytes t effecteurs à l'aide d'anticorps anti-cd127 pour des applications en thérapie cellulaire
KR20240056644A (ko) * 2018-05-10 2024-04-30 주식회사 뉴라클사이언스 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
EP3990496A4 (fr) * 2019-06-28 2023-08-09 The University of Melbourne Procédé d'inhibition ou d'activation de lymphocytes t gamma delta
US12552874B2 (en) 2019-11-26 2026-02-17 Ramot At Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
AU2021262748A1 (en) * 2020-04-27 2022-12-01 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting CD127 and use thereof
US20230183333A1 (en) * 2020-05-18 2023-06-15 Hassan Jumaa-Weinacht Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
EP2032695B1 (fr) 2006-05-31 2018-08-15 The Regents of The University of California Expression de cd127 inversement proportionnelle à foxp3 et fonction suppressive des tregs cd4+
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (fr) 2009-01-22 2010-07-29 University Of Miami Ciblage de la signalisation il-7 à des fins de traitement de la sclérose en plaques et d'autres troubles dépendant de la signalisation il-7
KR20130028055A (ko) 2010-01-28 2013-03-18 글락소 그룹 리미티드 Ｃｄ １２７ 결합 단백질
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
EP2583980A1 (fr) * 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
US20150297310A1 (en) * 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer
EP2955196A1 (fr) * 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127

Also Published As

Publication number Publication date
BR112018067479A2 (pt) 2019-01-15
KR20180118746A (ko) 2018-10-31
LT3423496T (lt) 2019-09-25
IL261330B (en) 2022-11-01
ES2737307T3 (es) 2020-01-13
IL261330A (en) 2018-10-31
MD3423496T2 (ro) 2020-01-31
PL3423496T3 (pl) 2020-01-31
CN109195987A (zh) 2019-01-11
RS59223B1 (sr) 2019-10-31
WO2017149394A1 (fr) 2017-09-08
AU2017225495B2 (en) 2024-05-09
MA43767A (fr) 2019-01-09
SMT201900460T1 (it) 2019-09-09
ME03446B (fr) 2020-01-20
SI3423496T1 (sl) 2019-10-30
KR102819051B1 (ko) 2025-06-12
IL261330B2 (en) 2023-03-01
US11230602B2 (en) 2022-01-25
JP2019515648A (ja) 2019-06-13
EP3423496A1 (fr) 2019-01-09
JP7053479B2 (ja) 2022-04-12
HUE045183T2 (hu) 2019-12-30
US20200308288A1 (en) 2020-10-01
CA3014313A1 (fr) 2017-09-08
AU2017225495A1 (en) 2018-08-23
DK3423496T3 (da) 2019-08-19
CN109195987B (zh) 2022-05-27
EP3423496B1 (fr) 2019-07-03
PT3423496T (pt) 2019-09-05
CY1122072T1 (el) 2020-11-25
HRP20191445T1 (hr) 2019-11-15

Similar Documents

Publication Publication Date Title
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
CY1122072T1 (el) Μη-ανταγωνιστικα αντισωματα κατευθυνομενα εναντι της αλφα αλυσου του εξωκυτταρικου πεδιου υποδοχεα il7 και χρηση αυτων σε θεραπεια καρκινου
PE20211902A1 (es) Receptores de citocinas quimericos constitutivamente activos
NZ789779A (en) Lilrb1-based chimeric antigen receptor
CL2016003172A1 (es) Anticuerpos dirigidos contra cd127
MX2025001902A (es) Construcciones de anticuerpos anti-ror
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
HN2012001223A (es) Antagonistas de pcsk 9
UA104663C2 (xx) Антитіло, що зв'язує cd127$антитело, связывающее cd127
WO2018124766A3 (fr) Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
JOP20200016B1 (ar) أجسام مضادة لـ cd137
MA49727A (fr) Anticorps et polypeptides dirigés contre cd127
EP3630980A4 (fr) Préparation cellulaire de récepteurs antigéniques chimériques et utilisations de celle-ci
MY194619A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
PH12020550930A1 (en) Human igg fc domain variants with improved effector function
GT201300150A (es) Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer
MA37945A1 (fr) Anticorps humains dirigés contre le gfr?3 et méthodes d'utilisation associées
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2020009465A (es) Anticuerpos anti-klk5 y metodos de uso.
MX2021012813A (es) Conjugados de citocina de liberacion lenta.
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
WO2021048564A3 (fr) Domaine de liaison à l'antigène
PH12020551985A1 (en) Anti-human tlr7 antibody